Evaluation of Therapeutic Effect and Safety of Different Methods in the Treatment of Adenomyosis With Pain

Comparing the Effects of Dienogest, LNG-IUS and Sanjiegutong Capsule in the Treatment of Symptomatic Adenomyosis: a Prospective Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002909

Enrollment

Unknown

Registered

2020-01-11

Start date

2019-12-31

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis

Interventions

Group A:dienogest

Group D:Sanjie Zhentong Capsule

Group B:LNG-IUS

Group C:dienogest + Sanjie Zhentong Capsule

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Premenopausal women aged 18 years or older; 2. Woman complains of menorrhagia or dysmenorrhea; 3. Women with ultrasonographic or MRI evidence of adenomyosis; 4. Be voluntory to this trial and sign the consent form .

Exclusion criteria

Exclusion criteria: 1. Woman who is pregnant or nursing; 2. Patients desire future pregnancy; 3. Unexplained uterine bleeding; 4. Receive other steroid hormone medications within 3 months; 5. Contraindications of treatment; 6. Women with uterine fibroids >=2 cm in diameter; 7. Women whose gynecological examination results were abnormal, or cervical cytology smear was abnormal in the past 3 months; 8. Women with abnormal blood clotting, other endocrine diseases, malignant or suspected malignant tumors.

Design outcomes

Primary

Measure	Time frame
Menstrual volume;Change in the size of uterus;FSH, LH, E2;Dysmenorrhea degree;	—

Secondary

Measure	Time frame
CA125;Hb;life quality score (QOL);Laboratory index;PGIC;	—

Countries

China

Contacts

Public ContactWang Baojin

307797362@qq.com+86 13523502380

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026